Clinical trials: Hepatitis C Virus (HCV)
Hepatitis C
Study of Patients With Chronic Hepatitis C Infected With HCV LVL G1 and Effect of Peg-Intron Plus Rebetol Treatment (Study P04793)
To determine the relapse rate at 24 weeks follow up in Hepatitis C Virus Genotype 1 Low Viral Load (HCV LVL G1) patients treated for 24 weeks with Peg Intron and Rebetol who are Hepatitis C Virus-Ribonucleic Acid (HCV-RNA)…
- Trial name
- NCT00709228
- Testing
- PegIntron, Rebetol
- Volunteers
- 496 people
- Sponsor
- Merck Sharp & Dohme LLC
Hepatitis C Virus (HCV) Infection
Development of a Community-based HCV Treatment Completion Intervention Among HCV Positive Homeless Adults
This randomized controlled trial (RCT) will test the efficacy of a Community Health Worker/Registered Nurse (CHW-RN) HCV intervention for homeless individuals, many who are also drug users.
- Trial name
- NCT04513899
- Testing
- Community health worker (CHW)/ registered nurse (RN) [CHW/RN], Clinic-based Standard of Care (cbSOC) Program (control group)
- Where
- 7 sites in United States
- Volunteers
- 10 people
- Sponsor
- University of California, Irvine
Chronic Hepatitis C
Efficacy and Safety Study of Peginterferon Alfa-2b in Chinese Chronic Hepatitis C Patients
The purpose of this study is to evaluate the efficacy and safety of Peginterferon alfa-2b (40KD, Y shape, the followings will refer as Ypeginterferon alfa-2b for short), at a dose of 180μg/week, in combination with Ribavirin in…
- Trial name
- NCT01581398
- Testing
- Ypeginterferon alfa-2b, Pegasys
- Where
- 42 sites in China
- Volunteers
- 770 people
- Sponsor
- Xiamen Amoytop Biotech Co., Ltd.
Hepatitis C Virus Infection
Study of Seraprevir in Combination With Sofosbuvir in Chronic Genotype 2,3,6 Hepatitis C Virus Infection Patients
This study was to assess the safety and efficacy of Seraprevir in combination with sofosbuvir in patients with Hepatitis C (HCV) genotype2,3,6.
- Trial name
- NCT04111367
- Testing
- Seraprevir, Sofosbuvir
- Where
- 4 sites in China
- Volunteers
- 36 people
- Sponsor
- Ginkgopharma CO., LTD
HIV Infections, Hepatitis B Infections
Rapid Diagnostics for HIV and Hepatitis
The purpose of this study is to determine the efficacy of two rapid diagnostic tests in plasma, venipuncture whole blood, and fingerstick whole blood.
- Conditions
- HIV Infections, Hepatitis B Infections, Hepatitis C Infections
- Trial name
- NCT02190305
- Testing
- Multiplo HBc/HIV/HCV and Reveal HBsAg
- Where
- 4 sites in United States
- Volunteers
- healthy volunteers welcome
- Sponsor
- MedMira Laboratories Inc.
Hepatitis C Virus
IFNL4 Genotype for Predicting Response to Ledipasvir/Sofosbuvir
Background: Hepatitis C virus (HCV) infection is a leading cause of hepatocellular carcinoma and end-stage liver disease. Ledipasvir/sofosbuvir is used to treat chronic HCV. The drug name for it is Harvoni.
- Trial name
- NCT03639207
- Sponsor
- National Cancer Institute (NCI)
Hepatitis C
Register of Telaprevir and Boceprevir in Routine Clinical Practice
Know through routine clinical practice the effectiveness and safety of current treatment of hepatitis C virus, genotype 1, for patients who have never been treated and for patients who have been previously treated
- Trial name
- NCT02004379
- Where
- 48 sites in Spain
- Volunteers
- 1,553 people
- Sponsor
- Fundación Pública Andaluza Progreso y Salud
Hepatitis C
Alisporivir With PEG and RBV in Protease Inhibitor (PI) Treatment Failure Patients With Chronic Hepatitis C
This study is to evaluate the overall efficacy, and safety profile of the triple combination therapy of alisporivir (ALV; DEB025) plus peginterferon alfa-2a (PEG) and ribavirin (RBV) patients with chronic hepatitis C (HCV)…
- Trial name
- NCT01500772
- Testing
- Alisporivir, Peginterferon alfa-2a, Ribavirin
- Where
- 60 sites in United States, Canada and 6 more
- Volunteers
- 6 people
- Sponsor
- Debiopharm International SA
Hepatitis C Infection
Safety and Efficacy of Daclatasvir (BMS-790052) Plus Standard of Care in Japanese Patients (Pegylated-interferon Alpha-2a and Ribavirin)
The purpose of this study is to identify at least 1 dose of Daclatasvir, that when combined with peginterferon-alfa (PegIFNα) and ribavirin (RBV) for the treatment of chronically infected HCV genotype 1 treatment-naïve and…
- Trial name
- NCT01017575
- Testing
- Daclatasvir, Peginterferon alfa-2a, Ribavirin
- Where
- 6 sites in Japan
- Volunteers
- 55 people
- Sponsor
- Bristol-Myers Squibb
Chronic Hepatitis C
The Effects of Adding TCM-700C on the Standard Combination Treatment for Patients With Genotype 1 Hepatitis C Infection
The primary objective of this study is to evaluate the effectiveness of TCM-700C as an add-on treatment to the combination drug therapy (Peginterferon α-2b plus Ribavirin) for patients with genotype 1 chronic hepatitis C…
- Trial name
- TCM-700C (NCT00556504)
- Testing
- TCM-700C, Peginterferon alfa-2a, Ribavirin
- Where
- Taiwan
- Volunteers
- 84 people
- Sponsor
- TCM Biotech International Corp.
Hepatitis C, Opioid Use Disorder
Rural New England Health Study (Phase 2)
This study will integrate mobile hepatitis C virus (HCV) testing and treatment with expanded syringe access in order to improve uptake of HCV testing and treatment, and reduce syringe sharing behavior in rural northern New…
- Conditions
- Hepatitis C, Opioid Use Disorder, IV Drug Usage
- Trial name
- DISCERNNE (NCT05466331)
- Testing
- Mobile Tele-HCV Care, Enhanced Usual Care
- Where
- 3 sites in United States
- Volunteers
- 220 people, healthy volunteers welcome
- Sponsor
- Baystate Medical Center
Hepatitis C Virus
PEG-IFN Plus Ribavirin Combination Therapy for Older Patients
The purpose of this study is to analyze the efficacy and safety of a combination therapy of pegylated interferon (PEG-IFN) alpha-2b plus ribavirin (RBV) for older Japanese patients (≧65years old) infected with hepatitis C virus…
- Trial name
- NCT00956982
- Testing
- Pegylated interferon alpha-2b plus ribavirin
- Where
- Japan
- Volunteers
- 1,251 people
- Sponsor
- Kyushu University
Chronic Hepatitis C
Efficacy and Safety of MP-424, Peginterferon Alfa-2b, and Ribavirin in Patients With Chronic Hepatitis C Who Relapsed After Previous Interferon Based Therapy
This study will evaluate the efficacy and safety of MP-424 with Peginterferon Alfa-2b (PEG-IFN) and Ribavirin (RBV) in patients with (Genotype 1) hepatitis C, who relapsed after previous treatment.
- Trial name
- NCT00780910
- Testing
- MP-424, Ribavirin, Peginterferon Alfa-2b
- Where
- Japan
- Volunteers
- 109 people
- Sponsor
- Tanabe Pharma Corporation
Alcohol Dependence, Chronic Hepatitis C
Study of the Effects of Motivational Enhancement Therapy on Alcohol Use in Chronic Hepatitis C Patients
The purpose of this study is to determine whether motivational enhancement therapy (MET) reduces alcohol use in a population of HCV-infected veterans who are currently drinking alcohol and have alcohol disorders.
- Trial name
- NCT00596960
- Testing
- Motivational Enhancement Therapy (MET), Health education
- Where
- 2 sites in United States
- Volunteers
- 139 people
- Sponsor
- US Department of Veterans Affairs
Hepatitis C, Chronic
Re-engaging Patients With Hepatitis C Into Care
Aims: To evaluate the impact of a letter, phone call and incentive in re-engaging patients with hepatitis C care. Outcomes of interest: Primary outcome of interest: Attendance for assessment of liver disease within 4 months of…
- Trial name
- NCT04029246
- Testing
- Follow up phone call, Incentive
- Where
- United Kingdom
- Volunteers
- 1,000 people
- Sponsor
- Glasgow Royal Infirmary
Hepatitis C
Hepatitis C Lab Testing Comparison Study
Hepatitis C (HCV) HCV antibody assays are the standard of care test used to screen for HCV, but confirmation of acute infection is relegated in the current US guidelines to polymerase chain reaction (PCR) which often takes…
- Trial name
- NCT06380166
- Testing
- Hepatitis C core antigen
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- HealthPartners Institute
Hepatitis C
Link Hepatitis C Notifications to Treatment in Tasmania
This project will utilise the notification process as a point of intervention to work with primary practitioners (GP) by contacting them directly when a notification of hepatitis C exposure is received by the Tasmanian department…
- Trial name
- NCT04510246
- Testing
- Enhanced case management
- Where
- Australia
- Volunteers
- 170 people, healthy volunteers welcome
- Sponsor
- Macfarlane Burnet Institute for Medical Research and Public Health Ltd
Hepatitis C, Chronic
Treating Hepatitis C in Pakistan. Strategies to Avoid Resistance to Antiviral Drugs
We will determine how best to manage the hepatitis C virus (HCV) epidemic in Pakistan by measuring effectiveness of Pakistan-government sponsored current therapies, emergence of viral resistance, consequences of infection…
- Trial name
- NCT04943588
- Testing
- HCV RNA (PCR), HCV Antibody test (Point of care), AST/ALT and platelets measurement
- Where
- Pakistan
- Volunteers
- 25,000 people, healthy volunteers welcome
- Sponsor
- Queen Mary University of London
Hepatitis C Virus Infection
Interventions to Curb Hepatitis C Reinfections Among Men Who Have Sex With Men
Men who have sex with men (MSM) who cured from hepatitis C virus (HCV) infection are at substantial risk of HCV reinfection. In this study, the investigators aim to evaluate the effectiveness of an online behavioural…
- Trial name
- ICECREAM (NCT04156945)
- Testing
- Behavioural intervention, HCV RNA home-based test
- Where
- 15 sites in France, Netherlands
- Volunteers
- 258 people
- Sponsor
- Public Health Service of Amsterdam
HCV, Hepatitis C Infection
Coadministration of ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) With Ribavirin (RBV) in Adults With Genotype 4 (GT4) Hepatitis C Virus (HCV) in Egypt
This study evaluates the efficacy and safety of ABT-450/r/ABT-267 with RBV in treatment-naive and treatment-experienced HCV GT4 subjects without or with compensated cirrhosis.
- Conditions
- HCV, Hepatitis C Infection, Genotype 4
- Trial name
- NCT02247401
- Testing
- 2 DAA, RBV
- Volunteers
- 160 people
- Sponsor
- AbbVie
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.